A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs GSK 3196165 (Primary) ; Folic acid; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2017 This trial was completed in Germany, according to European Clinical Trials Database.
- 04 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.